Article

Fluoroquinolones: do not taper dose

Tapering the dose of a topical fluoroquinolone at the end of a course of treatment is a great way to build up bacterial resistance. As such, doctors must not taper the dosage at the end of treatment.

Tapering the dose of a topical fluoroquinolone at the end of a course of treatment is a great way to build up bacterial resistance. As such, doctors must not taper the dosage at the end of treatment, according to Dr Richard L. Abbott.

"Fluoroquinolones are not like corticosteroids, where you might go from qid, tid, bid. With a fluoroquinolone, that's a great a way to build up resistance. The regimen should be qid for one week or two weeks postop and then stop," Dr Abbott told delegates at lunchtime symposium on antibiotic prophylaxis in cataract surgery sponsored by Santen.

The ESCRS, in its recently published guidelines on prevention, investigation and management of postoperative endophthalmitis, recommends that cataract surgeons consider using a topical fluoroquinolone. The regimen is four times a day for 48 or 24 hours prior to surgery, immediately postop, and up to two weeks afterwards. This is in addition to an intracameral cefuroxime injection that has become the proven prophylaxis regimen following the publication of the ESCRS Endophthalmitis study last year.

The ESCRS recommends a one-week postop regimen if a scleral tunnel or sutured clear cornea incision is used, and two weeks if with an unsutured clear corneal incision. The ESCRS guidelines cite levofloxacin or ofloxacin as the fluoroquinolone of choice, but note also that three studies indicate that levofloxacin gives three to four times higher levels of the active isomer in the anterior chamber.

Dr Abbott was hopeful that fluoroquinolones would remain a viable treatment for some time to come if doctors do not taper the dose.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.